Six renowned cancer research centers lead multiple collaborative networks to assess the cancer prevention potential of new agents in this Consortia focused on Phase I and II clinical trials. In addition to designing and conducting trials and recruiting participants, the Consortia works to characterize the effects of potential agents on molecular targets and biological events associated with cancer development, and to correlate these effects with clinical endpoints. These efforts promote further scientific insights into the mechanisms of cancer prevention, and the development of novel potential markers as determinants of response.
The Consortia aims to:
- Design and conduct early phase clinical trials to assess the cancer prevention potential of promising agents, many of which target molecules known to be evident during carcinogenesis.
- Characterize the effects of these agents on the molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression) and correlate these effects with clinical endpoints.
- Develop further scientific insights into the mechanism of cancer prevention by the agent examined and continue to develop novel potential markers as determinants of response.
The Consortia are led by outstanding nationally recognized cancer research centers. Consortia members and lead investigators (listed alphabetically by state) are:
- University of Arizona, Tuscon, AZ - David Alberts, MD & Sherry Chow, PhD
- University of California-Irvine, Irvine, CA - Frank Meyskens, MD
- Northwestern University, Evanston, IL - Raymond C. Bergan, MD & Lifang Hou, MD, PhD
- Mayo Clinic Foundation, Rochester, MN - Paul Limburg, MD, MPH
- M. D. Anderson Cancer Center, Houston, TX - Powel Brown, MD, PhD
- University of Wisconsin-Madison, Madison, WI - Howard Bailey, MD
Clinical Trials Resource Step-by-Step Instructions for Consortia Members
Back to top
